Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastases.

ABSTRACT:

Objective

Osteosarcoma is the most common primary bone sarcoma. About 50% of patients develop metastatic disease and their 5-year survival lingers at around 20%-30%. T cell checkpoint blockade immunotherapies have revolutionised cancer treatment in the last decade, but their impact remains limited in osteosarcoma.

Methods and analysis

In order to reveal potentially novel immunotherapeutic strategies for advanced osteosarcoma, we conducted an immunogenomic characterisation of a unique sample set comprising 30 osteosarcoma samples from seven patients, collected throughout disease progression. We performed RNA-sequencing and imaging mass cytometry analysis on these samples to reveal the immunological landscape during osteosarcoma progression.

Results

Transcriptional and

SUBMITTER: Meijer DM 

PROVIDER: S-EPMC11880787 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature